-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Minimally Invasive Brain Science (02172.HK) issued an announcement. The Artemis Dream® Chanjuan™ self-inflating intracranial rapamycin-eluting stent system (Artemis Dream®) developed by Minimally Invasive Shentong Medical Technology (Shanghai) Co., Ltd., a subsidiary of the Group, passed the National Drug Administration (NMPA) special review application for innovative medical devices and entered the special review process (green channel). Up to now, the Group has included 7 products in the NMPA special review for innovative medical devices. The inclusion of this product marks another official recognition of the technical layout in the field of treatment of intracranial artery stenosis.

Zhitongcaijing·07/30/2026 00:25:05
Listen to the news
Zhitong Finance App News, Minimally Invasive Brain Science (02172.HK) issued an announcement. The Artemis Dream® Chanjuan™ self-inflating intracranial rapamycin-eluting stent system (Artemis Dream®) developed by Minimally Invasive Shentong Medical Technology (Shanghai) Co., Ltd., a subsidiary of the Group, passed the National Drug Administration (NMPA) special review application for innovative medical devices and entered the special review process (green channel). Up to now, the Group has included 7 products in the NMPA special review for innovative medical devices. The inclusion of this product marks another official recognition of the technical layout in the field of treatment of intracranial artery stenosis.